Next Article in Journal
Wnt/β-Catenin Signaling in Oral Carcinogenesis
Next Article in Special Issue
Signaling Pathways That Control Muscle Mass
Previous Article in Journal
Sleep Duration, Lipid Profile and Insulin Resistance: Potential Role of Lipoprotein(a)
Previous Article in Special Issue
Progressive Skeletal Muscle Atrophy in Muscular Dystrophies: A Role for Toll-Like Receptor-Signaling in Disease Pathogenesis
Open AccessReview

Emerging Strategies Targeting Catabolic Muscle Stress Relief

School of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, UK
Department of Experimental and Molecular Cardiology, TU Dresden, Heart Center Dresden, 01307 Dresden, Germany
Dresden Cardiovascular Research Institute and Core Laboratories GmbH, 01067 Dresden, Germany
Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany
Myomedix GmbH, Im Biengarten 36, 69151 Neckargemünd, Germany
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(13), 4681;
Received: 4 June 2020 / Revised: 26 June 2020 / Accepted: 29 June 2020 / Published: 30 June 2020
(This article belongs to the Special Issue Muscle Atrophy: Discovery of Mechanisms and Potential Therapies)
Skeletal muscle wasting represents a common trait in many conditions, including aging, cancer, heart failure, immobilization, and critical illness. Loss of muscle mass leads to impaired functional mobility and severely impedes the quality of life. At present, exercise training remains the only proven treatment for muscle atrophy, yet many patients are too ill, frail, bedridden, or neurologically impaired to perform physical exertion. The development of novel therapeutic strategies that can be applied to an in vivo context and attenuate secondary myopathies represents an unmet medical need. This review discusses recent progress in understanding the molecular pathways involved in regulating skeletal muscle wasting with a focus on pro-catabolic factors, in particular, the ubiquitin-proteasome system and its activating muscle-specific E3 ligase RING-finger protein 1 (MuRF1). Mechanistic progress has provided the opportunity to design experimental therapeutic concepts that may affect the ubiquitin-proteasome system and prevent subsequent muscle wasting, with novel advances made in regards to nutritional supplements, nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) inhibitors, myostatin antibodies, β2 adrenergic agonists, and small-molecules interfering with MuRF1, which all emerge as a novel in vivo treatment strategies for muscle wasting. View Full-Text
Keywords: atrophy; diaphragm; disuse; mitochondria; MuRF1; MuRF2; skeletal muscle; ubiquitin; wasting atrophy; diaphragm; disuse; mitochondria; MuRF1; MuRF2; skeletal muscle; ubiquitin; wasting
Show Figures

Figure 1

MDPI and ACS Style

Scalabrin, M.; Adams, V.; Labeit, S.; Bowen, T.S. Emerging Strategies Targeting Catabolic Muscle Stress Relief. Int. J. Mol. Sci. 2020, 21, 4681.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop